542 related articles for article (PubMed ID: 28814429)
1. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
Huang J; Maier C; Zhang Y; Soare A; Dees C; Beyer C; Harre U; Chen CW; Distler O; Schett G; Wollin L; Distler JHW
Ann Rheum Dis; 2017 Nov; 76(11):1941-1948. PubMed ID: 28814429
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
[TBL] [Abstract][Full Text] [Related]
3. The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease.
Wollin L; Trinh-Minh T; Zhang Y; Distler JHW
Clin Exp Rheumatol; 2021; 39 Suppl 131(4):134-141. PubMed ID: 33886452
[TBL] [Abstract][Full Text] [Related]
4. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Wollin L; Maillet I; Quesniaux V; Holweg A; Ryffel B
J Pharmacol Exp Ther; 2014 May; 349(2):209-20. PubMed ID: 24556663
[TBL] [Abstract][Full Text] [Related]
5. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis.
Maurer B; Reich N; Juengel A; Kriegsmann J; Gay RE; Schett G; Michel BA; Gay S; Distler JH; Distler O
Ann Rheum Dis; 2012 Aug; 71(8):1382-7. PubMed ID: 22523431
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Adenosine Deaminase Ameliorates Inflammation, Vascular Disease, and Fibrosis in Preclinical Models of Systemic Sclerosis.
Zhang Y; Zhu H; Layritz F; Luo H; Wohlfahrt T; Chen CW; Soare A; Bergmann C; Ramming A; Groeber F; Reuter C; Fornasini G; Soukhareva N; Schreiber B; Ramamurthy S; Amann K; Schett G; Distler JHW
Arthritis Rheumatol; 2020 Aug; 72(8):1385-1395. PubMed ID: 32182396
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation.
Tsutsumi T; Nagaoka T; Yoshida T; Wang L; Kuriyama S; Suzuki Y; Nagata Y; Harada N; Kodama Y; Takahashi F; Morio Y; Takahashi K
PLoS One; 2019; 14(7):e0214697. PubMed ID: 31339889
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease.
Soldano S; Smith V; Montagna P; Gotelli E; Campitiello R; Pizzorni C; Paolino S; Sulli A; Cere A; Cutolo M
Arthritis Res Ther; 2024 Mar; 26(1):74. PubMed ID: 38509595
[TBL] [Abstract][Full Text] [Related]
10. Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis.
Avouac J; Guignabert C; Hoffmann-Vold AM; Ruiz B; Dorfmuller P; Pezet S; Amar O; Tu L; Van Wassenhove J; Sadoine J; Launay D; Elhai M; Cauvet A; Subramaniam A; Resnick R; Hachulla E; Molberg Ø; Kahan A; Humbert M; Allanore Y
Arthritis Rheumatol; 2017 Nov; 69(11):2209-2221. PubMed ID: 28805015
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease.
Liu F; Wang L; Qi H; Wang J; Wang Y; Jiang W; Xu L; Liu N; Zhuang S
Clin Sci (Lond); 2017 Aug; 131(16):2125-2143. PubMed ID: 28646122
[TBL] [Abstract][Full Text] [Related]
12. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
13. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity.
Sato S; Shinohara S; Hayashi S; Morizumi S; Abe S; Okazaki H; Chen Y; Goto H; Aono Y; Ogawa H; Koyama K; Nishimura H; Kawano H; Toyoda Y; Uehara H; Nishioka Y
Respir Res; 2017 Sep; 18(1):172. PubMed ID: 28915889
[TBL] [Abstract][Full Text] [Related]
14. ATRA ameliorates fibrosis by suppressing the pro-fibrotic molecule Fra2/AP-1 in systemic sclerosis.
Pi Z; Liu J; Xiao Y; He X; Zhu R; Tang R; Qiu X; Zhan Y; Zeng Z; Shi Y; Xiao R
Int Immunopharmacol; 2023 Aug; 121():110420. PubMed ID: 37331293
[TBL] [Abstract][Full Text] [Related]
15. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
16. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
[TBL] [Abstract][Full Text] [Related]
17. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease.
Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS
Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease.
Kavian N; Servettaz A; Marut W; Nicco C; Chéreau C; Weill B; Batteux F
Arthritis Rheum; 2012 Jun; 64(6):1990-2000. PubMed ID: 22213155
[TBL] [Abstract][Full Text] [Related]
19. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide demonstrates efficacy in a mouse model of preclinical systemic sclerosis.
Cauvet A; Decellas A; Guignabert C; Rongvaux-Gaïda D; Thuillet R; Ottaviani M; Tu L; Rieger F; Avouac J; Allanore Y
Arthritis Res Ther; 2023 Sep; 25(1):167. PubMed ID: 37700377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
